StemCell Therapy

1 - 15 of 6,981 jobs

Global Personnel Search Inc

Columbus, OH

Analytical ScientistColumbus, OHPosition Description:This Ph.D. Analytical Scientist (R&D) position will be responsible for leading the project from feasibility phase to commercial launch. We are...

posted 1 day ago

Bio Partners Search Group, LLC

Northern, Nj, NJ

The Associate Director, Commercial Analytics is responsible for supporting Marketing/Sales and Managed Care Markets Management in the following key areas: physician targeting, segmentation, sample...

posted 1 day ago

KOB Solutions, Inc.

Paramus, NJ

My client is actively recruiting for a Director of Clinical Operations to develop the internal infrastructure of this growing firm and oversee clinical trials operations. The ideal candidate will...

posted 1 day ago

Gallin Associates

Norristown, PA

Job Profile:Manager to oversee major key manufacturing transfer programs for a world class medical device manufacturer. The position will be responsible for managing the transfer of manufacturing...

posted 1 day ago

Med Exec Intl / MEIRxRS

Los Angeles, CA

VP Clinical & Regulatory Affairs needed in Los Angeles, CAVP Clinical and Regulatory Affairsneeded to develop and implement clinical studies and molecular diagnostics validation strategy. The...

posted 1 day ago

CHLOETA

Boise, ID

CHLOETA is a dynamic incident management firm that conducts and plans operations nationwide for a variety of public and private sector clients. Incident Management Team (IMT) ReservistAs an IMT...

posted 1 day ago

Regency Search Group

South Bend, IN

Company BackgroundFor 30 years, this research laboratory has been manufacturing and distributing a variety of enzymes and cofactors used in basic coagulation research. They are known and trusted by

posted 1 day ago

Spark Therapeutics, Inc

Philadelphia, PA

Individual with strong pharmacology and toxicology experience in developing AAV-based therapies. The candidate will be responsible for the strategy and execution of pharmacology and toxicology...

posted 2 days ago

Stabilis Professional Services

Andover, MA

Stabilis Professional Services, Inc. is looking for aBioinformatics Software Developer for their client in Andover, MA.Responsibilities: Designs, codes, tests, corrects and documents moderately...

posted 2 days ago

Excelsior Recruiting Group

New York, NY

BENEFITSCompetitive base starting at 90k plus commissionExcellent Benefits packageCompany CarGreat Growth Opportunity!!!QUALIFICATIONS Minimum of 10 years of sales & project experience in packaging

posted 3 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Research Scientist is a member of the Liver Discovery Research functional group within the Discovery Research group under Translational Research. He/she will be responsible for: Design and...

posted 4 days ago

Continental Search and Outplacement, Inc.

Indianapolis, IN

Leading company in animal agriculture seeks experienced sales professional to grow their market share in Indiana, Ohio and northern Kentucky. Candidates can live anywhere within the region andwork...

posted 4 days ago

Philadelphia, PA

The Assay Development Associate - Vector Shedding/Bio Distribution will: With guidance and supervision from the group leader or supervisor, conduct clinical and preclinical sample analysis per SOPs...

posted 4 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Sr. Regulatory Operations Specialist contributes to daily operations activities for preparation of regulatory submissions to FDA, EMA, and other key health authorities. They also collaborate...

posted 4 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Head of Medical Science Liaisons (MSL) will be responsible for helping to build and lead Spark MSL team(s). This position will define the objectives of the MSL function, including building...

posted 4 days ago

Originally posted here:
BioTech Jobs in the BioTechnology Pharmaceuticals Industry

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture.

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine.

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2016 is analyzed and the market is projected to 2026.

The text is supplemented with 35 tables and 5 figures.Selected 260 references from the literature are appended.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/mdr33b/animal

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/animal-biotechnology-technologies-markets-and-companies-2016-2026-with-profiles-of-the-top-companies---research-and-markets-300452977.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Original post:
Animal Biotechnology Technologies, Markets and Companies 2016 ... - PR Newswire (press release)

Puma Biotechnology Inc.s stock took a dive last week after its regulatory executive resigned less than three weeks before a U.S. Food and Drug Administration panel is scheduled to review the public companys breast cancer drug Neratinib.

The Westwood companys share price dipped 14 percent to $31.38 at the close of business May 5 from $36.45 the day before, when the company notified the Securities and Exchange Commission that Robert Charnas, senior vice president of regulatory affairs and project management, would step down for health reasons effective May 15.

The stock was trading at $29.15 when the markets closed Monday.

The company, which has a market cap of $1.07 billion, hired 63-year-old Charnas last year with a base salary of more than $330,000, stock options, and a more than $378,000 signing bonus, according to the employment offer letter filed with the SEC.

An independent panel of experts is scheduled to review Neratinib for safety and efficacy May 24 before making a recommendation for its use to the FDA.

Caroline Anderson is a staff reporter covering retail, restaurants, and hospitality. She can be reached at canderson@labusinessjournal.com.

More here:
Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review - Los Angeles Business Journal

Barron's

ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain Barron's Meanwhile the SPDR S&P Biotech ETF (XBI), the SPDR S&P Pharmaceuticals ETF (XPH), and the First Trust NYSE Arca Biotechnology Index (FBT) fell about 2.7% apiece. The AHCA could have both positive and negative impact on pharma and biotech, but ...

Follow this link:
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain - Barron's

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a rough trading day for Monday May 08 as shares tumbled 5.54%, or a loss of $-1.7 per share, to close at $29.00. After opening the day at $30.45, shares of Puma Biotechnology Inc traded as high as $31.20 and as low as $28.50. Volume was 1.11 million shares over 8,212 trades, against an average daily volume of 941,762 shares and a total float of 36.97 million.

As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.07 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $38.11 and 200-day SMA is $43.37.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

See the rest here:
Puma Biotechnology Inc (PBYI) Plunges 5.54% on May 08 - Equities.com

Puma Biotechnology, Inc. (PBYI) belongs to the Healthcare sector with an industry focus on Biotechnology, with Mr. Alan H. Auerbach as Founder, Chairman, Chief Exec. Officer, Pres and Sec..

The company has been one of the biggest innovators in Biotechnology.

Key Statistics:

Financials:

The company reported an impressive total revenue of 0 in the last fiscal year.

If you look at the companys income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, PBYI earned gross profit of 0, in 2015 0 gross profit, while in 2016 Puma Biotechnology, Inc. (PBYI) produced 0 profit.

Currently the shares of Puma Biotechnology, Inc. (PBYI) has a trading volume of 4.25 Million shares, with an average trading volume of 1220 shares with shares dropping to a 52 week low of $19.74, and the companys shares hitting a 52 week high of $ 73.27.

Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Puma Biotechnology, Inc. the EPS stands at -2.04 for the previous quarter, while the analysts predicted the EPS of the stock to be -1.92, suggesting the stock fell short of the analysts expectations.

Another critical number in evaluating a stock is P/E or the price to earnings ratio.

The TTM operating margin is 0%. The return on invested capital at 0%, which is good, compared to its peers.

The Free Cash Flow or FCF margin is 0%.

Stock is currently moving with a negative distance from the 200 day simple moving average of approximately -29.35%, and has a solid year to date (YTD) performance of 0% which means the stock is constantly adding to its value from the previous fiscal year end price.

Future Expectations:

The target price for Puma Biotechnology, Inc. (PBYI) is $79/share according to the consensus of analysts working on the stock, with an expected EPS of $-1.98/share for the current quarter.

Read more:
Puma Biotechnology, Inc. Posted losses of -16.01% in the Last ... - Free Observer

NY Stock News

The Charts Expose On Puma Biotechnology, Inc. (PBYI) Is Causing A Stir NY Stock News The technicals for Puma Biotechnology, Inc. (PBYI) have taken shape, and with them a comprehensive picture has emerged. This is the current state of play as presented by the current technical setup. Reading the technical chart for a given stock is a ...

See more here:
The Charts Expose On Puma Biotechnology, Inc. (PBYI) Is Causing A Stir - NY Stock News

What happened

Puma Biotechnology(NASDAQ:PBYI) stock has plummeted 18.2% as of 12:53 p.m. EDT following news that Dr. Robert Charnas, its head of regulatory affairs and project management, is hitting the exits ahead of a scheduled Food and Drug Administration (FDA) advisory panel meeting on May 24.

Puma Biotechnology has only one product in its clinical-stage drug pipeline, and that drug, neratinib, has been the subject of a lot of scrutiny after trials showed that a large number of patients taking it suffered from high-grade diarrhea.

Image source: Getty Images.

Puma Biotech's CEO Alan Auerbach hired Charnaslast year to help get neratinib across the regulatory finish line. Previously,Charnas worked at Johnson & Johnson in its research and development department. He was responsible for ongoing development of Zytiga, a prostate cancer drug that J&J acquired in 2009 when it bought Auerbach's previous company, Couger Biotech. Charnas joined Cougar in 2008.

Yesterday, Puma Biotech said Charnas is leaving because of health reasons. However, there's some conflicting information circulating that there may have been some disagreements between him and his co-workers. If so, no one is saying for sure what those disagreements were about.

News of his departure so close to the FDA advisory committee meeting is disconcerting, regardless of Charnas' reasons for leaving.

After all, neratinib is far from a lock to win the committee's recommendation for approval. It's being considered as an extended maintenance therapy to help delay disease recurrence in breast cancer patients who have previously been treated for one year with Herceptin. In trials, neratinib hit its mark in terms of efficacy, but many of its patients reported severe diarrhea.

In hopes of overcoming a rejection because of this safety risk, Puma Biotech has been studying the use of the anti-diarrhea drug loperamide and steroids alongside neratinib. Ideally, a diarrhea incidence rate below 20% would be desirable, but interim trial results showed a 27% rate of grade 3 or higher diarrhea when using loperamide. Steroids may lower that rate further, but their use can cause other unwanted side effects.

It's anyone's guess what will happen at the advisory committee meeting, or what the FDA will ultimately decide to do with neratinib's application. Nevertheless, I think the risk of failure is too high to recommend buying shares ahead of a decision.

Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The rest is here:
Why Puma Biotechnology Shares Are Crashing 18.2% Today - Motley Fool

The Cerbat Gem

iShares NASDAQ Biotechnology Index (IBB) Position Maintained by Ausdal Financial Partners Inc. The Cerbat Gem iShares NASDAQ Biotechnology Index logo Ausdal Financial Partners Inc. continued to hold its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) during the first quarter, according to its most recent Form 13F filing with the SEC. The ... Appleton Partners Inc. MA Cuts Stake in iShares NASDAQ Biotechnology Index (IBB)Transcript Daily Commerzbank Aktiengesellschaft FI Has $20.843 Million Stake in iShares NASDAQ Biotechnology Index (IBB)Markets Daily iShares NASDAQ Biotechnology Index Sees Unusually Large Options Volume (IBB)Sports Perspectives BBNS -Chaffey Breeze -Community Financial News all 44 news articles »

See the original post:
iShares NASDAQ Biotechnology Index (IBB) Position Maintained by Ausdal Financial Partners Inc. - The Cerbat Gem

The stock market performed reasonably well on Friday, sending major benchmarks to gains of 0.25% to 0.5% on the day. Favorable news from the U.S. economy outweighed any concerns about geopolitical events occurring this weekend, including the much-awaited final phase of the French elections. The Dow regained the 21,000 level, and the S&P 500 finished just below the 2,400 mark. But some stocks missed out on the rally, and Puma Biotechnology (NASDAQ:PBYI), Trex (NYSE:TREX), and National CineMedia (NASDAQ:NCMI) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly.

Shares of Puma Biotechnology fell 16% after the biotech company said in an SEC filing that an executive in charge of regulatory affairs and project management would resign from the company effective May 15. The filing said that Dr. Robert Charnas had told Puma last week about his departure, with the filing citing health reasons for the move. Yet investors seem to be nervous about the timing, coming immediately before a key advisory panel meeting for its neratinib treatment for breast cancer. Given that neratinib has seen patients in trials report negative side effects, some investors believe that Puma might have trouble getting a positive recommendation from the panel when it meets later this month. The stock's decline might prove to be an overreaction, but the company's decision to put the information in a filing rather than doing a full press release might have contributed to investors' skepticism about the move.

Image source: Trex.

Trex stock declined 9% in the wake of the company releasing its first-quarter financial results. The home deck and railing specialist said that sales climbed 10% from year-ago figures, with increasing margins helping to produce an 18% rise in net income. Trex has gotten a lot of accolades from its industry, including kudos for its environmentally friendly practices and its leadership role in promoting alternatives to traditional wood decking and railing materials. Yet guidance for sales of $160 million in the second quarter only matched investor expectations, and despite calls for improving market share and margin figures, Trex investors seemed to want more from the decking specialist as the high spring season for home improvement begins.

Finally, shares of National CineMedia lost more than a quarter of their value. The in-theater media company said that revenue was down 6% from the year-ago quarter, leading to a drop in operating income and a wider net loss compared to the first quarter of 2016. Despite gains in sales from its local and regional segment as well as its digital and beverage businesses, softness in national advertising revenue weighed on the company's overall results. CEO Andy England reiterated that he sees 2017 as "a transitional year for NCM as we evolve from being the largest cinema network into a truly progressive, integrated digital media company." That means investors have to expect tough results this year, and National CineMedia's guidance called for revenue to fall 1% to 6% and produce a 6% to 12% drop in adjusted operating income. As movie theaters struggle to get people to leave their homes for entertainment, National CineMedia will have to work harder to find new avenues for growth.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Trex. The Motley Fool has a disclosure policy.

See the original post:
Why Puma Biotechnology, Trex, and National CineMedia Slumped Today - Motley Fool

isW%}~dL6_bZge&Y,@@`"@P$[}=>_"+YdTx?]r]Ze__Grj}}}^m_"}^mgoZ]~ 7_mw_^mgWOO;]t^e<=w5>b)"Wm/WQ}uW__J_gz>nkm/'qS7Jnw~uTsqU1_.jw8_;[(g+rz{K,.l|+b__^4urU6|}~Ye"u^m! Ung^e6tZe'"h.?.;Y]_vn|]z=N|/rq'>N :|{~wzmO*~ugw2;/?d'}-6x]]l[e-nVM|zvUlbz>fw^V.`nlq^~_,W{y~#?ooS|/7}D];w7-M]Wq7~x-a)yluyv~Z/znW8(/7>;ENq"_|z.t<=m_,,.>&//^)]#mmG)r:8xpW*;,KkjkBU:'XU>,NS~ T[<*mw6'nG;i'Q9'i,ydgd?PL$ys_v:+Ers~o6oK_eQF9_GS|y~~/7(+cw{7WYSqSE~3G1rtq#MGj"_EFcl}qmV)K_UcJg}jW.Nap89.?D,C6>U~uslQ>}U?NclO|__+Q^V;&z;v[7gynV+k#>-O]E]Ylrkvt'HeU4j=mkzqVM[u'.)M46B}Z&T]h_6qbVKM9nb76t)+_.Nb]-lk[_/57xiOd1~P9sjNMp''[dysSu~wO esrU-MS -vhW|UfmCP./VN5,7qmKLEhlK]Y{/4>5_h[hyXuUvTu(&:iOx|:s"y4 raLaqE;Y6(@g)4 jyZ,}5=We=.|[W`]WZTv=Y'<9]Y_97WuVQ2_G|"*ju _./)]l'Ocz%WgvpRD~93?yw}snj]>l__-KyZz0#s[]W:l^LX>5~~,/"}YkQyGwov=gqnT_mYxKvxkO8W]*t&wfLvB~z-#I;GVrurS.^>KwTik#o8` cN$?(VL248o7W3 O.Nc+37OMQNd&{&~w:|fA6)Z+|M9oFM^ns1d)={^_o?ZG>ms=X~/.64}3z6)+n_LS.Wg_gu:k!e ,!1S7xZ1U6Qe5r;-,~SWvOUoz`t/)hwnun[Q{@gXR]M9Vr2SxCv1In%zN#}=<]~zwBp}?niN}OX%9FmVS>#z[#nh7dyC%rw8$5ARz,!e'$}3}"i'$- *ssN&snWo&#O}N;xCNNHoQNN&ONXFu-sG ZlgQJ>nQcX9l5A`=R]Vv7r.8|5W!dln"tQkte|M jz>L\T=2de}3%X!R{W;2Q5=:kT7|Nebf33.'q]$xNj4:scNBnL==K<.afdoHC,|h{n#v]u'e3K< X}$IOX9c[`d9/":d9&(u 8&{z#zx0/O-4(36tCjs]]pYh/IZ!o(Z{l{92?OlrTB1|VwA{}OG?.=VzO? AU>mzjqouwz[u0F(!D}:t>O(;.0D#O dw(2I[Q&]JwuWz2=7B)xk1'VpyA :

<[`859tyRsj]ut4MISik"MOUsCsQ9'?;S14|dA z~6v'SSQ}W_3?3r>Od4+?wGKpmo2' XcX+,1{ VKA00s;0BwrS<#gp`':4Sg*E~;kV. ~u6u5<;>4,)Fh>e7~LS#c5Q33.)ll0QC&+ym~N8E?-r~[*8eDMRLR6]CcJw{]~#,n6't|]3xRqsLJysY2dYM&}^ME>^&de^g~=_q;S|N?d>Gq;T)o-!9#(g~mXBf (>k^L[[} (}({+dy }xB(l}pBsg%qM~X">_2an.UQUR&KQO;pKw;V5Q^oQ`Y1"3t.?K"=PxTc5RT|*oVrfCEqJ / WupTQnJ7^]^?b,h/ hoIO}S[L+IjdvK>M?&`:!wZXohl{'qB&qLyBS j>e/Z__CxZQ7u2QEY>?~__/rt8v(V5zWOWGXoRSlFq?vw.]C2[oxN4G//vkn}~|fyE_H+ji*j{o!/GsW5*|I"C3AyuaHsA+Mt J4qerEiGo%D qA&.EA;!m~:>17Col[ynFR7R)X9@Fb}M|y|_7OF.QxN;+G'TrBC")bP5p$ GD*ID+ w`)rv-B'@hqK4 #:0Y8bhgdU|jnE/ ky{7lyQ=hH c [j15H6*h0pL"{;Lm,,i%9 .NadQh2_(az3FD..(t 8qdxdZtY!lvmuAkve Lu# ,~-q .SfS&B+Qo,o]aBF)-`} l(1ynBXy7u5j/ 1L(rEpdWAo!#`RT(?cd"v-"bE Um tlVx^ J|#&g@!ZCjR"eDp^]lp~X%b) ,|d]pc:Drzb=>lxk2[8$7cQPBU#sAW5Xe84E'DmDa, *qZbdV)HS&C,nc7@$y}F#Rt$#-)vhl:Nx:SK^<]rPz:!.R1O[:ao@Eh;`|HqShS]$s{`xH^HI2>6.wM@oV=[~t.JHHQR7~R&t#m)wy*D!U)pTO 9.fQW!O:f! jjO":R)lD|N~"oI1GPd'a)^TTA"6HQ:'q8SJHD2850?j!R_q9MR=J7tB;RldIn2qg?4Y C lARti@4 X`$v"oI>o+6E]*nH^J@xYo[j_bU6YX8'BH6 5VDT|or1W #b+tA7+!;]K=-vAMxFW9o$011I^2N1YGJ#q_TDBQ[IaU*p"KaB`2x oh* )]KgQs-I">J8*JG*korDZ@]LB}o&~f#y# 9mo,bK/r! +c

C.J,JQh/lee(@Y&?-hErR$QI0KYVjEFUso]i7B`0fFSYuy i98$hBqIy-F!;@ab075W v( hhgh gk.+f^)R!^q/:Y:.WR +[$;Y er6>O6m*T:PGqG]"W17y+K8jKg HC?xjFt'CC&;0t`XD ~g^e-DFPU(*<`Gw %H9$0?=Qi9% r<&tn)Dc*{ %0{2@K] $m2),u">k1(JK+{hX;:@Z"}^;PZJ/) &GRN4f' pKQpi wU9 viD(E18Rv4rjmG``6O#r(&^3 'xZ5k'Dz{@?w!.|%V}Qb(d u!^7fX3?__._#fUV!V:@7P&k0Q]42Jxja1qlI:j2 33JVa8JI%ryS0Xs*)vC5-3ehFp@F=GV#tu4*|e M.QU t=8*JUJ``&tK6I a~Gqu,(w5G,4+.l)`EiXhhs {ieBq%!/YTfW`)B~[f"#+Lk.Em417 L3Xg< fr lMFmii5COlA;BJA/^%i0jK6g*i3lYS*9bsDH51APuk ~5QG:dYLHh Edo$COOt>n9Y mqb${dx%#xu@%%w%wqn%omOwozc}kk)]kJ=,ufS>qx(5O$,W|YK;PL&fm 3Hs'{72is5Tp<:iA#KDdM~,!^B"~PTt^2xLP:Q&J^DTBiJm3)91&cO2gH@nO pxfM-[HS@E^ %b&_jb 6Odv7)"2dXAR@dBE#7E" >9DcNCFz]}$ [t-* =BpK=sm*FjT*0#dkFKDTH3K^]`Pfr1~n*q]T*T@Eop}}`r d D^wiH/5h60<3pq(`-h&T)M8#wq^;G G:},+ 2O51LnM|`/+nCJ&h7([6; aWxx%8f? A]Zdp'b% _QML%S wc HF)HlS:1L`NU0fgUEzYoXaSs! 90GwYi?LfEo%#411=^o8- (shJ'k!%b2{ aW"K$=K#+1~O{Je;a~J-yB`YcNIt(m6aaCBDBf T!(#ak~HtG6(WxVs0H'][:;5/)=" IqaMX/KhHDG)"`haF#AzyhOU,irs@H)g~i0 8v ZKX/Q(>Aa <.%G9d#CXDb>OF-I%fDTq4MSh%t@=,fIfAd.q)BXHU3aE=QZi'fT$9U Uy^?{G1?L?|VmQ}Huzi?2g)+d j2I7J{Iw20,)/9hH45e/dLWOCRsut0Q5pOnB(hYUU|JPgs27h4*B)7d6.:Xa" ._!I$Q'tX1 y(cu.^$1E~JbYbZ]p2J:=vH{1f6+8T4MC 04A(sK/maF{RQEIL 9LI?U5=r(y~6Jh v( EQM#)e(4 G{ ar$AYvrl4O[O?}FeUxbch!1z't~o$YL3 Bd}D1MaL^L}8RSSB?4Pmz& ^dK~z!gax9p2CP42gEw-c 2^6iZC/6%@#(iQD,ajw 6cIPS%d77=|j};lJ2b<@t32E'~E-,Q)^A)!<_*pRXUgzBENf0a *:8#5Z0]#NNai!vG,Aje?B}e 6*uj{5|vm[]6o["1B1}_IihX!2*CO+:UDDe=FL'v fkA6&/1{?|P^0 22Zm-ZuVx?ZM#tgY60CKa;)*vYvj[;p_$VJBmb! ;FkK!dxKQ4*Ah^`/9Myl$JS]' PEd`vT'QG@X35bTf0Yub|.^emi~H6 SMd/`%t=.J!P 0@-q%i:af,}{n%g`5XzJWB4WXFxN}n8%GE$[@ !XcT*B+DXH1LQG->ZX5(8kR$qW!d)jvwp;|$-fYYB NRTjjX1UU 2}B c!<" $GA i=6va(d4dh$YMgIHLlyB(AkvN$C_Om=fNDrPUz#[T7c9k]rUb "ORw VD8{&kCA=Z% m$EO}:W"s_&kfIa{SOPc"g_F-V2)A]j-|*Kh&V/A!9x,LTi!)F>8SyBTvw&w{!=j.PxYUA# 6Al&AD?O`6<6!v 2)PbQ8C5 X aC;d ck(|eH6nvxS%ni;FVZEzb> {JnJ&h$5]1J0>jg^t4lI/+vX o`(bnQ:d#> VN&>HisVRj>N}4#g^Gu>Q1u9 Xms&pHo C@Y>LOM*,Ofnb{Lhz=ACv@aWj? @rOQ5 nRhT6"{wDR 9LZ g~T+#( {KF89qzp5,BgndJ]uw DU1H%C0xA29`_faqPDY8m %;cQO8X$}4:ePxz-8fW^RqH2&E pBSa18W;?U`0n,:O:qjtS2Sezj|#9vLGb'R}/_zhdk ['z8QP|mA^$ 3d L2$b,Q2t;Fs0-+Yul,Yd"pc%lL)-24$0P(?Su'F B{GJFG6H#Ic#qi3#!) flPcV&JRzLsg1 6L!W%bAm.18AAjB%3X'j{^FaT+ ?heZ,$SYDmOa_4Mg{leb {#[QE3mNz5}(DQ EXyFBP&pHX#( *Fx lHGpTU$Cp$%s(3B%nn$hkTTI De*+,"WUHRyC6P@`d-}7-y8T')T%w'B2J))y5[ z JHJj3] 9:^K@A`SJMT0&(H(wyp'x(k`>yJ:[0`@I^uI AvUb;dXs#=- cTZJH EuPD|,?n}3aSR#n(l40 `Ub`"jyT3jJ:6g';A`1SU2[1W~ XKa9f0U M:=R_Q7}&n(t+1P$9L"=bK{g5;.QS[KAXFfpa( V)@xfjX)8uS(?FL0#W :

Read the original:
Cell-free biotech will make for better products - The Economist